Dengue history must be based on a recorded laboratory confirmation of past acute infection, which could have been tested at the time of infection by a direct diagnostic method such as polymerase chain reaction (PCR) or NS1 antigen to detect (part of) the virus or using an indirect diagnostic method such as dengue-specific serology to detect anti-dengue antibodies by ELISA or an RDT (WHO WER, 2018).
A booster dose of Dengvaxia® is not recommended. although existing clinical data on a booster dose of Dengvaxia® did not show any deleterious impact in terms of the immune or safety profile, the absence of any meaningful impact on the humoral response did not support an additional benefit of a booster dose. Therefore we do not recommend a booster dose in seropositive patients at this time.
Dengvaxia must not be administered to individuals with congenital or acquired immune deficiency that impairs cell-mediated immunity, including immunosuppressive therapies such as chemotherapy or high doses of systemic corticosteroids generally given for 2 weeks or more.
In the indicated population, the most common side effects of the vaccine (any severity/grade) include headache, injection-site pain, malaise and myalgia. These side effects are usually mild to moderate and resolve within 2–3 days (Gailhardou et al., 2016).
This person doesn’t need to repeat the first dose and continue to receive the 2nd dose.
During the Active Phase of CYD14, efficacy by country was consistent with the overall estimate the VE against VCD. The point estimates of VE in Thailand was similar to those in Philippines and in Indonesia, where no public JE vaccination program is implemented. It is still unclear whether pre-exposure of other flaviviruses could affect the efficacy or immune responses of dengue vaccines.
CYD-TDV has demonstrated prevention against symptomatic infections, as well as asymptomatic infections. Consequently, it could contribute to reducing viral transmission and thus to indirect protection if the vaccine coverage rates are sufficient. However, since CYD-TDV is now indicated only for people with prior dengue infection, it would be difficult to achieve vaccine coverage rates in a population, at which the herd effect could be identified.
Yes. Many epidemiological factors such as population growth, global climate change, increased urbanization, migration and international trade can increase the proliferation and expansion of mosquito vectors (Grange et al., 2014)
Symptoms of Covid and acute dengue can be similar. Timely laboratory diagnosis (such as PCR) is the key to differentiate these two infections.
Persons with laboratory-confirmed history of dengue in their medical records can be considered to receive Dengvaxia, without the need of serotesting. Therefore a well-established database of confirmed dengue cases could help to identify individuals with prior dengue exposure. Dengue vaccination should ideally be performed 1–6 months after acute infection.